Last reviewed · How we verify
SIIV
At a glance
| Generic name | SIIV |
|---|---|
| Sponsor | Hipra Scientific, S.L.U |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age (PHASE3)
- A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 (PHASE2)
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age (PHASE3)
- Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age (PHASE3)
- A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults (PHASE2)
- Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIIV CI brief — competitive landscape report
- SIIV updates RSS · CI watch RSS
- Hipra Scientific, S.L.U portfolio CI